نتایج جستجو برای: sustained virology response svr

تعداد نتایج: 1047399  

Journal: :journal of research in medical sciences 0
maryam keshvari seyed moayed alavian bita behnava ali pouryasin heidar sharafi

background: a dinucleotide variant rs368234815 in interferon lambda 4 (ifnl4) gene was recently found to be associated with the hepatitis c virus (hcv) treatment response. this study aimed to assess the impact of ifnl4 rs368234815 polymorphism on treatment response to pegylated?ifn alpha (peg?ifn??) and ribavirin (rbv) in hemophilic patients with chronic hepatitis c (chc). materials and methods...

Ali Kabir, Hadi Ghofrani, Hossein Foroutan Pishbijary, Seyed Moayed Alavian, Shahram Mirmomen,

Introduction: The aim of this study is to assess the therapeutic efficacy and safety of a particular brand of IFN alpha (PDferon B®) in combination with ribavirin (RlBA) on Iranian patients with chronic hepatitis C (CHC). The addition of RIBA to the standard treatment with interferon (IFN) alpha led to an improvement in sustained virologic response (SVR) from less than 20% with IFN monother...

اخوندی میبدی, محسن, امیربیگی, محمدکاظم, سلمان روغنی, حسن, عزیزی, ریحانه,

Introduction: Based on data from recent trials, peginterferon and ribavirin combination therapy is the standard of care in treating patients with chronic HCV infection, but because of high costs, many patients may deprive from treatment. Methods: We conducted a clinical trial on HCV patients in Yazd in gastroenterology clinic. Thirty patients received conventional subcutaneous interferon alf...

بافنده , یوسف, باقری لنکرانی , کامران, صابری فیروزی , مهدی,

Background and purpose: About 200,000 of Iranian population are infected with Hepatitis C Virus. On the basis of Iranian consensus on management of chronic hepatitis C (CHC) infection in 2004, combination therapy with conventional α-Interferon (IFN) plus Ribavirin is the first therapeutic choice in CHC patients. Data are limited on treatment response rate in most areas of the country. To asse...

Journal: :hepatitis monthly 0
maissa el raziky department of endemic medicine and hepatology, cairo university, cairo, egypt waleed fouad fathalah department of endemic medicine and hepatology, cairo university, cairo, egypt; department of endemic and hepatology, cairo university, cairo, egypt , +20-233444921 wafaa ahmed el-akel department of endemic medicine and hepatology, cairo university, cairo, egypt ahmed salama department of endemic medicine and hepatology, cairo university, cairo, egypt gamal esmat department of endemic medicine and hepatology, cairo university, cairo, egypt mahassen mabrouk department of endemic medicine and hepatology, cairo university, cairo, egypt

background egypt has one of the highest (16-8%) prevalence rates of hcv infection in the world. approximately 90% of egyptian hcv isolates belong to a single subtype (4a), which responds less successfully to interferon therapy than other subtypes. studies comparing the efficacy and safety of pegifn alfa-2a and pegifn alfa-2b in treatment-naive hcv-infected patients have shown conflicting result...

2016
Robert Flisiak Joanna Pogorzelska Hanna Berak Andrzej Horban Iwona Orłowska Krzysztof Simon Ewelina Tuchendler Grzegorz Madej Anna Piekarska Maciej Jabłkowski Zbigniew Deroń Włodzimierz Mazur Marcin Kaczmarczyk Ewa Janczewska Arkadiusz Pisula Jacek Smykał Krzysztof Nowak Marek Matukiewicz Waldemar Halota Joanna Wernik Katarzyna Sikorska Iwona Mozer-Lisewska Błażej Rozpłochowski Aleksander Garlicki Krzysztof Tomasiewicz Joanna Krzowska-Firych Barbara Baka-Ćwierz Wiesław Kryczka Dorota Zarębska-Michaluk Iwona Olszok Anna Boroń-Kaczmarska Barbara Sobala-Szczygieł Bronisława Szlauer Bogumiła Korcz-Ondrzejek Jerzy Sieklucki Robert Pleśniak Agata Ruszała Barbara Postawa-Kłosińska Jolanta Citko Anna Lachowicz-Wawrzyniak Joanna Musialik Edyta Jezierska Witold Dobracki Beata Dobracka Jan Hałubiec Rafał Krygier Anna Strokowska Wojciech Chomczyk Krystyna Witczak-Malinowska

THE AIM OF THE STUDY Was to analyze the efficacy achieved with regimens available for chronic hepatitis C (CHC) in Poland between 2013 and 2016. MATERIAL AND METHODS Data were collected from 29 centers and included 6786 patients with available sustained virologic response (SVR) data between 1 January 2013 and 31 March 2016. RESULTS The sustained virologic response rate for genotypes (G) 1a,...

Journal: :hepatitis monthly 0
najmeh namazee infectious disease and tropical medicine research center, shahid beheshti university of sciences, ir iran shahnaz sali infectious disease and tropical medicine research center, shahid beheshti university of sciences, ir iran sorour asadi infectious disease and tropical medicine research center, shahid beheshti university of sciences, ir iran mostafa shafiei research center for gastroenterology and liver diseases, baqiatallah university of sciences, mollasadra st., vanak sq., p. o. box: 141553651, ir iran +98-2188067114, [email protected] bita behnava research center for gastroenterology and liver diseases, baqiatallah university of sciences, mollasadra st., vanak sq., p. o. box: 141553651, ir iran +98-2188067114, [email protected] seyed moayed alavian research center for gastroenterology and liver diseases, baqiatallah university of sciences, mollasadra st., vanak sq., p. o. box: 141553651, ir iran +98-2188067114, [email protected]; research center for gastroenterology and liver diseases, baqiatallah university of sciences, mollasadra st., vanak sq., p. o. box: 141553651, ir iran +98-2188067114, [email protected]

background despite significant advances in the treatment of chronic hepatitis c in the past decades, factors which can affect response rates to combination therapy; peginterferon and ribavirin, are still under study and reaching sustained virological response (svr) is affected by several different factors. objectives to investigate predictor factors contributing to svr in iranian patients. pati...

Journal: :medical journal of islamic republic of iran 0
seyed moayed alavian dept. ofgastoenterology, baqiyatallah university of medical sciences; the department of gastroenterology, imam khomeiniسازمان اصلی تایید شده: دانشگاه علوم پزشکی بقیه الله (baqiyatallah university of medical sciences) hossein foroutan pishbijary dept. ofgastoenterology, baqiyatallah university of medical sciences; the department of gastroenterology, imam khomeiniسازمان اصلی تایید شده: دانشگاه علوم پزشکی بقیه الله (baqiyatallah university of medical sciences) shahram mirmomen imam khomeini hospital, endoscopy ward, tehran, iranسازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (tehran university of medical sciences) hadi ghofrani dept. ofgastoenterology, baqiyatallah university of medical sciences; the department of gastroenterology, imam khomeiniسازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (tehran university of medical sciences) ali kabir dept. ofgastoenterology, baqiyatallah university of medical sciences; the department of gastroenterology, imam khomeiniسازمان اصلی تایید شده: دانشگاه علوم پزشکی بقیه الله (baqiyatallah university of medical sciences)

introduction: the aim of this study is to assess the therapeutic efficacy and safety of a particular brand of ifn alpha (pdferon b®) in combination with ribavirin (rlba) on iranian patients with chronic hepatitis c (chc). the addition of riba to the standard treatment with interferon (ifn) alpha led to an improvement in sustained virologic response (svr) from less than 20% with ifn monotherapy ...

Journal: :The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 2006
E Parise H Cheinquer D Crespo A Meirelles A Martinelli H Sette J Gallizi R Silva C Lacet E Correa H Cotrim J Fonseca R Paraná V Spinelli W Amorim F Tatsch M Pessoa

Peginterferon alfa plus ribavirin is currently the treatment of choice for chronic hepatitis C. Peginterferon alfa-2a (40KD) plus ribavirin has given an overall sustained virological response of 18% in F3/F4 previous nonresponder US patients. We evaluated the effectiveness of peginterferon alfa-2a (40KD) plus ribavirin in Brazilian patients who were relapsers or nonresponders to previous interf...

Journal: :hepatitis monthly 0
heidar sharafi iran hepatitis network, tehran, ir iran; middle east liver diseases center (meld), tehran, ir iran seyed moayed alavian iran hepatitis network, tehran, ir iran; middle east liver diseases center (meld), tehran, ir iran maryam keshvari iran hepatitis network, tehran, ir iran; middle east liver diseases center (meld), tehran, ir iran; blood transfusion research center, high institute for research and education in transfusion medicine, tehran, ir iran; blood transfusion research center, high institute for research and education in transfusion medicine, tehran, ir iran. tel: +98-2188601501-30, fax: +98-2166900386

background previous studies using pegylated interferon (peg-ifn) and ribavirin (rbv) combination therapy suggested that patients with hepatitis c virus (hcv) genotype 1 and low pretreatment hcv rna level who achieved rapid virological response (rvr) can be treated for 24 weeks without compromising sustained virological response (svr) rate. objectives the current study aimed to investigate the e...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید